Clinical Trials Logo
  1. Home
  2. Cachexia
  3. NCT05865535

A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia

Cachexia Clinical Trial

Official title:
A Phase 1 Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels

Clinical Trial Summary

This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in metastatic cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05865535
Study type Interventional
Source AVEO Pharmaceuticals, Inc.
Contact AVEO Clinical Trials Office
Phone (857)400-0101
Email clinical@aveooncology.com
Status Recruiting
Phase Phase 1
Start date June 13, 2023
Completion date September 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05603585 - Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients N/A
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Completed NCT01696604 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT02567773 - Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078 Phase 1
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Active, not recruiting NCT00710632 - Screening to Predict Weight Loss in Patients With Cancer N/A
Completed NCT00031785 - Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer Phase 3
Withdrawn NCT02017925 - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation N/A
Recruiting NCT01829880 - Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure N/A
Completed NCT01419145 - A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study N/A
Completed NCT01692990 - Study on the Effect of Fish Oil and Appetite Phase 0
Completed NCT01015274 - Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
Completed NCT00994669 - Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients N/A
Terminated NCT00962234 - Metabolism of Lipids in Advanced Cancer N/A
Terminated NCT00851448 - Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients N/A
Completed NCT00972634 - Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer N/A
Terminated NCT00535015 - Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer Phase 2
Terminated NCT00558558 - Haelan and Nutrition in Cancer Patients Phase 2